SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to increased 2025 revenue guidance driven by strong DefenCath sales and the Melinta portfolio. The community is discussing the raised guidance and potential for further growth, with some expressing excitement about the company's future prospects. Broader discussions include CorMedix's strategic investment in Talphera and potential impacts of upcoming clinical data.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending due to a widespread AWS outage impacting numerous services and applications, sparking concerns about the reliability of centralized infrastructure. The community is discussing the extent of the disruption and its potential financial repercussions, while also questioning Amazon's ability to maintain its competitive edge in cloud computing and AI amid the issues.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors are closely watching for potential asset sales and a possible foreign partnership, highlighted by a recent Memorandum of Understanding with a major global steel producer. Community discussions revolve around the impact of this MoU and potential buyout scenarios, alongside the company's strategic position in the US steel market. Additionally, tariffs and macro data surrounding the steel and automotive industries remain key talking points for CLF.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

CELC is trending due to positive Phase 3 trial data for its breast cancer therapy, gedatolisib, showing a significant reduction in disease progression risk, leading to community excitement and analyst upgrades. The community is discussing the potential for FDA approval, buyout scenarios, and the impact on treatment standards, while also noting the possibility of a near-term offering. However, some caution against shorting and potential overvaluation, recognizing the strong positive data, while others suggest a pullback is imminent.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending due to promising data from its PATHFINDER 2 study, highlighting the potential of its Galleri multi-cancer early detection test; the study results pave the way for FDA submission. Community members are discussing the potential for Medicare coverage and revenue growth, especially with support in Congress, and Samsung's commitment to marketing in Asia. The company is also presenting at the Jefferies Global Healthcare Conference on Wednesday.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following positive Phase II data, leading to a trading halt and sparking community discussion around a potential 'crazy spike' upon unhalting. Bullish sentiment is further fueled by analyst upgrades and price target increases, with some speculating about a potential retail squeeze. The community is also closely watching for further developments regarding RAPT's next-generation CCR4 antagonist.

Safe Pro Group, Inc. engages in the provision and acquisition of security and protection products. Its products include Artificial Intelligence (AI) and Machine Learning (ML) software technology and photogrammetry analysis tools, bullet and blast resistant personal protection equipment, and aerial managed services and mission-critical uncrewed solutions. The firm operates through the following segments: Safe-PRO USA, Airborne Response, and Safe Pro AI. The company was founded by Daniyel Erdberg on December 15, 2021 and is headquartered in Aventura, FL.

Safe Pro Group Inc

SPAI is trending due to a strategic investment of $14 million, with community members pointing to this as a sign of confidence in the company's AI-based drone technology. Bullish sentiment is fueled by potential breakout setups, high trading volume, and the company's expansion in the Asia-Pacific region. Discussions also highlight Safe Pro Group's collaborations and its role in landmine detection using AI, positioning it as a key player in the defense and security sector.

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is trending due to a recently announced strategic partnership, sparking excitement among investors. The community is focused on the potential impact of the partnership, especially given the stock's low float and history as a runner. Some traders believe the stock is due for a significant upward move, while others caution about potential dilution and volatility.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NCNA is trending due to encouraging data releases and regulatory approvals regarding their oncology assets, sparking optimism within the community. Bullish investors are actively discussing the potential for significant price appreciation, fueled by the company's compelling early efficacy in chemo-resistant settings. Some traders are drawing comparisons to other low floaters and anticipating a large move, highlighting the upcoming presentation at the ESMO congress.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

OMER is trending due to a recent licensing deal with Novo Nordisk for a potential $2.1 billion, leading to a significant price surge and high trading volume. The community is actively discussing the potential for a short squeeze, the likelihood of FDA approval for Narsoplimab, and speculation around future royalty payments. Some traders express concern about potential retracement and manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


tgo88net

Go88